Log in to search using one of your social media accounts:

 

Celebrating 10 years of success for Infusion

As the business took off, more space was needed, and the company moved in 2009 to “real” office space just up the road in Haddam, CT, across the street from the Connecticut River, eventually employing a staff of 10 that year. A year later, in 2010, Infusion had doubled in size and became part of the UDG/Ashfield family. Infusion continued to grow at a steady pace into new therapeutic areas with more clients and employees, and in October 2016, Infusion left its country setting and moved into larger corporate offices in downtown Middletown, CT. Our staff now comprises 45 people and includes account executives, medical writers, scientific directors, medical editors, and graphic designers. Three of the four original employees still work at Infusion (Matt, Angela, and Rick Kemmerer), and many of us have been here 5+ years. It’s the challenge of the work and the quality of the people we work with that gets us into the office every day and keeps us here long-term. Some 90% of our scientific staff have advanced degrees, and our management team has 18+ years of experience in healthcare communication; our scientific team 10+ years; our core delivery team 10+ years; and client services 8+ years. Heather Sylvestro, our Director of Graphics and Production, is an award-winning designer, having been recognised several times by professional advertising/graphics industry groups for her designs and having had her design chosen as the artwork for the 2014 annual meeting of th...
Source: Ashfield Healthcare News - Category: Pharmaceuticals Authors: Tags: Ashfield Source Type: news

Related Links:

A new study in a mouse model of MS reveals two ways in which Th1 and Th17 immune cells cross the blood-barrier to attack the central nervous system.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news
No abstract available
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: Review Article Source Type: research
No abstract available
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: Original Articles Source Type: research
No abstract available
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: Original Articles Source Type: research
No abstract available
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: Original Articles Source Type: research
We report the successful use of ceftolozane/tazobactam (C/T) to treat a pulmonary exacerbation in a 35 year old female, post lung transplant, with cystic fibrosis (CF), malnutrition, chronic kidney disease, and multi-drug resistant Pseudomonas aeruginosa infection (MDR PSA). Given the complexity of the clinical profile, we measured drug levels of C/T during treatment of her current exacerbation to determine pharmacokinetics. The patient achieved an estimated ceftolozane peak of 174.1 μg/mL and trough of 9.2 μg/mL. Serum half-life was found to be slightly shorter than previously reported in normal subjects, (2.3 hr. v...
Source: Respiratory Care - Category: Respiratory Medicine Authors: Tags: Respir Med Case Rep Source Type: research
ConclusionThe IPSG score appears applicable to not only the TTJ but also the STJ. Contrary to TTJ lesions, those of the STJ do not correlate with the HJHS but do with 3D‐rearfoot kinematic data.
Source: Haemophilia - Category: Hematology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well‐established favorable safety profile. The short antigenic polypeptide sequences comprising therapeutically active epitopes in GA cannot be deciphered with state‐of‐the‐art methods; and GA has no measurable pharmacokinetic profile and no validated pharmacodynamic markers. The study reported herein describes the use of orthogonal standard and high‐resolution physicochemical and biological tests to characterize GA and a U.S. Food and Drug...
Source: Annals of the New York Academy of Sciences - Category: Science Authors: Tags: ORIGINAL ARTICLE Source Type: research
New therapies for hemophilia A and hemophilia B will likely continue to change clinical practice. Ranging from extended half-life to nonfactor products and gene therapy, these innovative approaches have the potential to enhance the standard of care by decreasing infusion frequency to increase compliance, promoting prophylaxis, offering alternatives to inhibitor patients, and easing route of administration. Each category has intrinsic challenges that may limit the broader application of these promising therapies. To date, none specifically address the challenge of dispersing treatment to the developing world.
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Thrombosis and Hemostasis, Blood Spotlight, Clinical Trials and Observations, Gene Therapy Source Type: research
We report the clinical presentation of and identify biomarkers of severe CRS in 133 adult patients who received CD19 CAR T cells. CRS developed in 70% of patients, including 62.5% with grade 1 to 3 CRS (grade 1, 26%; grade 2, 32%; grade 3, 4.5%), 3.8% with grade 4, and 3.8% with grade 5. A majority of cases of grade ≥4 CRS occurred during CAR T-cell dose finding. Multivariable analysis of baseline characteristics identified high marrow tumor burden, lymphodepletion using cyclophosphamide and fludarabine, higher CAR T-cell dose, thrombocytopenia before lymphodepletion, and manufacturing of CAR T cells without selection o...
Source: Blood - Category: Hematology Authors: Tags: Immunobiology and Immunotherapy, Clinical Trials and Observations Source Type: research
More News: Acromegaly | Advertising | Cancer & Oncology | Conferences | Cystic Fibrosis | Haemophilia | Hemophilia | Multiple Sclerosis | Pharmaceuticals | Politics | Primary Immunodeficiency Disease | Rare Diseases | Training | Universities & Medical Training | von Willebrand Disease